

REMARKS

The claims have been amended to conform them to an invention not elected in the parent, that of group IV of the restriction requirement, drawn to piperazine compounds. Claim 1 has been amended to conform to this election and to conform to the corresponding wording in claim 1 as allowed in the parent. (In the parent application piperidine derivatives were claimed.) Claim 2 was canceled as no longer pertinent. Claim 9 was amended to clarify the symbols used in the structures shown. Claims 8, 10, 16-18, 21, 26, 32, 39, 42, 46, 50 and 51 have been amended to correct typographical errors.

Claims 22, 27, 33, 34, 37 and 38 have been canceled as either directed to non-elected inventions or as redundant.

Claim 53 has been amended so as to depend on claim 1 rather than spelling out the formula once again. Claim 54 has been canceled. Claim 57 has also been amended to depend from claim 1 and claim 58 has been canceled. Claim 60 has been amended in accordance with allowed claim 60 in the parent application. No new matter has been added and entry of the amendment is respectfully requested.

The claims as currently amended correspond to the allowed claims in the parent except that the compounds of the invention are piperazine rather than piperidine derivatives. Accordingly, it is believed that the claims as presented are in a position for immediate allowance.

A revised abstract is submitted on the attached paper.

In the unlikely event that the transmittal letter is separated from this document and the Patent Office determines that an extension and/or other relief is required, applicants petition for any required relief including extensions of time and authorize the Assistant Commissioner to

charge the cost of such petitions and/or other fees due in connection with the filing of this document to **Deposit Account No. 03-1952** referencing docket No. 219002029210.

Respectfully submitted,

Dated: January 7, 2004

By: Kate H. Murashige
Kate H. Murashige
Registration No. 29,959

Morrison & Foerster LLP
3811 Valley Centre Drive,
Suite 500
San Diego, California 92130-2332
Telephone: (858) 720-5112
Facsimile: (858) 720-5125